Search Press releases

25 Sep 2024

UCB presents new 4-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe plaque psoriasis at EADV 2024

Read More
24 Sep 2024

Transparency notification BlackRock, Inc.

Read More
24 Sep 2024

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Read More
23 Sep 2024

UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis

Read More
9 Sep 2024

New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease

Read More
6 Sep 2024

Transparency notification BlackRock, Inc.

Read More

Stay up-to-date on the latest news and information from UCB